BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 21292688)

  • 1. Chromosome 17 alterations identify good-risk and poor-risk tumors independently of clinical factors in medulloblastoma.
    McCabe MG; Bäcklund LM; Leong HS; Ichimura K; Collins VP
    Neuro Oncol; 2011 Apr; 13(4):376-83. PubMed ID: 21292688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.
    Pfister S; Remke M; Benner A; Mendrzyk F; Toedt G; Felsberg J; Wittmann A; Devens F; Gerber NU; Joos S; Kulozik A; Reifenberger G; Rutkowski S; Wiestler OD; Radlwimmer B; Scheurlen W; Lichter P; Korshunov A
    J Clin Oncol; 2009 Apr; 27(10):1627-36. PubMed ID: 19255330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early recurrence in standard-risk medulloblastoma patients with the common idic(17)(p11.2) rearrangement.
    Bien-Willner GA; López-Terrada D; Bhattacharjee MB; Patel KU; Stankiewicz P; Lupski JR; Pfeifer JD; Perry A
    Neuro Oncol; 2012 Jul; 14(7):831-40. PubMed ID: 22573308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
    Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
    Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytogenetic evaluation of isochromosome 17q in posterior fossa tumors of children and correlation with clinical outcome in medulloblastoma. Detection of a novel chromosomal abnormality.
    DeChiara C; Borghese A; Fiorillo A; Genesio R; Conti A; D'Amore R; Pettinato G; Varone A; Maggi G
    Childs Nerv Syst; 2002 Aug; 18(8):380-4. PubMed ID: 12192498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients.
    Pan E; Pellarin M; Holmes E; Smirnov I; Misra A; Eberhart CG; Burger PC; Biegel JA; Feuerstein BG
    Clin Cancer Res; 2005 Jul; 11(13):4733-40. PubMed ID: 16000568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic classification of pediatric medulloblastoma based on chromosome 17p loss, expression of MYCC and MYCN, and Wnt pathway activation.
    Park AK; Lee SJ; Phi JH; Wang KC; Kim DG; Cho BK; Haberler C; Fattet S; Dufour C; Puget S; Sainte-Rose C; Bourdeaut F; Grill J; Delattre O; Kim SK; Park WY
    Neuro Oncol; 2012 Feb; 14(2):203-14. PubMed ID: 22090452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and molecular stratification of disease risk in medulloblastoma.
    Gilbertson R; Wickramasinghe C; Hernan R; Balaji V; Hunt D; Jones-Wallace D; Crolla J; Perry R; Lunec J; Pearson A; Ellison D
    Br J Cancer; 2001 Sep; 85(5):705-12. PubMed ID: 11531256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification.
    Korshunov A; Remke M; Werft W; Benner A; Ryzhova M; Witt H; Sturm D; Wittmann A; Schöttler A; Felsberg J; Reifenberger G; Rutkowski S; Scheurlen W; Kulozik AE; von Deimling A; Lichter P; Pfister SM
    J Clin Oncol; 2010 Jun; 28(18):3054-60. PubMed ID: 20479417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromosome 1q gain is not associated with a poor outcome in childhood medulloblastoma: requirements for the validation of potential prognostic biomarkers.
    Clifford SC; O'Toole K; Ellison DW
    Cell Cycle; 2009 Mar; 8(5):787. PubMed ID: 19221477
    [No Abstract]   [Full Text] [Related]  

  • 11. Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial.
    Clifford SC; Lannering B; Schwalbe EC; Hicks D; O'Toole K; Nicholson SL; Goschzik T; Zur Mühlen A; Figarella-Branger D; Doz F; Rutkowski S; Gustafsson G; Pietsch T;
    Oncotarget; 2015 Nov; 6(36):38827-39. PubMed ID: 26420814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accumulation of genomic aberrations during clinical progression of medulloblastoma.
    Korshunov A; Benner A; Remke M; Lichter P; von Deimling A; Pfister S
    Acta Neuropathol; 2008 Oct; 116(4):383-90. PubMed ID: 18704466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic alterations in childhood medulloblastoma analyzed by comparative genomic hybridization.
    Michiels EM; Weiss MM; Hoovers JM; Baak JP; Voûte PA; Baas F; Hermsen MA
    J Pediatr Hematol Oncol; 2002; 24(3):205-10. PubMed ID: 11990307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gain of 1q is a potential univariate negative prognostic marker for survival in medulloblastoma.
    Lo KC; Ma C; Bundy BN; Pomeroy SL; Eberhart CG; Cowell JK
    Clin Cancer Res; 2007 Dec; 13(23):7022-8. PubMed ID: 18056178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of chromosome 17 abnormalities in medulloblastomas.
    Aldosari N; Rasheed BK; McLendon RE; Friedman HS; Bigner DD; Bigner SH
    Acta Neuropathol; 2000 Apr; 99(4):345-51. PubMed ID: 10787031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chromosome 17 abnormalities in medulloblastomas and their prognostic value].
    Korshunov AG; Sycheva RV; Gorelyshev SK; Ozerov SS; Golanov AV
    Zh Vopr Neirokhir Im N N Burdenko; 2008; (2):3-5; discussion 5. PubMed ID: 18724421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.
    Ellison DW; Kocak M; Dalton J; Megahed H; Lusher ME; Ryan SL; Zhao W; Nicholson SL; Taylor RE; Bailey S; Clifford SC
    J Clin Oncol; 2011 Apr; 29(11):1400-7. PubMed ID: 20921458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of chromosome 17p loss with clinical outcome in medulloblastoma.
    Emadian SM; McDonald JD; Gerken SC; Fults D
    Clin Cancer Res; 1996 Sep; 2(9):1559-64. PubMed ID: 9816333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma.
    Korshunov A; Remke M; Kool M; Hielscher T; Northcott PA; Williamson D; Pfaff E; Witt H; Jones DT; Ryzhova M; Cho YJ; Wittmann A; Benner A; Weiss WA; von Deimling A; Scheurlen W; Kulozik AE; Clifford SC; Peter Collins V; Westermann F; Taylor MD; Lichter P; Pfister SM
    Acta Neuropathol; 2012 Apr; 123(4):515-27. PubMed ID: 22160402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of chromosome 17p deletions in childhood primitive neuroectodermal tumors (medulloblastomas) of the central nervous system.
    Biegel JA; Janss AJ; Raffel C; Sutton L; Rorke LB; Harper JM; Phillips PC
    Clin Cancer Res; 1997 Mar; 3(3):473-8. PubMed ID: 9815707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.